Ritter Pharmaceuticals Competitors

Ritter Pharmaceuticals (NASDAQ:RTTR) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Ritter Pharmaceuticals and Eagle Pharmaceuticals, as reported by MarketBeat.

Eagle Pharmaceuticals has a consensus target price of $52.50, indicating a potential upside of 12.90%. Given Eagle Pharmaceuticals' higher probable upside, analysts plainly believe Eagle Pharmaceuticals is more favorable than Ritter Pharmaceuticals.

Volatility and Risk

Ritter Pharmaceuticals has a beta of -0.43, suggesting that its share price is 143% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Institutional & Insider Ownership

0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.7% of Eagle Pharmaceuticals shares are owned by institutional investors. 15.4% of Ritter Pharmaceuticals shares are owned by company insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ritter Pharmaceuticals and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ritter Pharmaceuticals and Eagle Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than Ritter Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Ritter Pharmaceuticals on 11 of the 11 factors compared between the two stocks.

IVERIC bio (NASDAQ:ISEE) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Volatility and Risk

IVERIC bio has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500.

Insider and Institutional Ownership

85.7% of IVERIC bio shares are owned by institutional investors. Comparatively, 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. 4.3% of IVERIC bio shares are owned by insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares IVERIC bio and Ritter Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for IVERIC bio and Ritter Pharmaceuticals, as provided by MarketBeat.com.

IVERIC bio currently has a consensus target price of $13.00, suggesting a potential upside of 106.35%. Given IVERIC bio's higher possible upside, research analysts clearly believe IVERIC bio is more favorable than Ritter Pharmaceuticals.

Earnings & Valuation

This table compares IVERIC bio and Ritter Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Ritter Pharmaceuticals has lower revenue, but higher earnings than IVERIC bio.

Summary

IVERIC bio beats Ritter Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations for Geron and Ritter Pharmaceuticals, as provided by MarketBeat.

Geron currently has a consensus target price of $4.00, suggesting a potential upside of 120.99%. Given Geron's higher possible upside, equities analysts clearly believe Geron is more favorable than Ritter Pharmaceuticals.

Insider & Institutional Ownership

50.4% of Geron shares are held by institutional investors. Comparatively, 0.8% of Ritter Pharmaceuticals shares are held by institutional investors. 7.7% of Geron shares are held by company insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Geron and Ritter Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Ritter Pharmaceuticals has lower revenue, but higher earnings than Geron.

Risk & Volatility

Geron has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500.

Profitability

This table compares Geron and Ritter Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Geron beats Ritter Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

74.1% of Mirum Pharmaceuticals shares are held by institutional investors. Comparatively, 0.8% of Ritter Pharmaceuticals shares are held by institutional investors. 45.5% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Mirum Pharmaceuticals has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Mirum Pharmaceuticals and Ritter Pharmaceuticals, as reported by MarketBeat.com.

Mirum Pharmaceuticals currently has a consensus target price of $40.60, indicating a potential upside of 86.75%. Given Mirum Pharmaceuticals' higher probable upside, research analysts clearly believe Mirum Pharmaceuticals is more favorable than Ritter Pharmaceuticals.

Valuation & Earnings

This table compares Mirum Pharmaceuticals and Ritter Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Mirum Pharmaceuticals and Ritter Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Mirum Pharmaceuticals beats Ritter Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Ritter Pharmaceuticals (NASDAQ:RTTR) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Profitability

This table compares Ritter Pharmaceuticals and Organogenesis' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ritter Pharmaceuticals and Organogenesis' gross revenue, earnings per share and valuation.

Ritter Pharmaceuticals has higher earnings, but lower revenue than Organogenesis.

Risk & Volatility

Ritter Pharmaceuticals has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Institutional & Insider Ownership

0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.2% of Organogenesis shares are owned by institutional investors. 15.4% of Ritter Pharmaceuticals shares are owned by company insiders. Comparatively, 70.4% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Ritter Pharmaceuticals and Organogenesis, as reported by MarketBeat.

Organogenesis has a consensus price target of $9.25, suggesting a potential upside of 80.66%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Ritter Pharmaceuticals.

Summary

Organogenesis beats Ritter Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Odonate Therapeutics (NASDAQ:ODT) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Institutional and Insider Ownership

95.4% of Odonate Therapeutics shares are held by institutional investors. Comparatively, 0.8% of Ritter Pharmaceuticals shares are held by institutional investors. 48.9% of Odonate Therapeutics shares are held by company insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Odonate Therapeutics and Ritter Pharmaceuticals' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Odonate Therapeutics and Ritter Pharmaceuticals, as provided by MarketBeat.com.

Odonate Therapeutics presently has a consensus target price of $38.00, suggesting a potential upside of 167.42%. Given Odonate Therapeutics' higher possible upside, equities research analysts plainly believe Odonate Therapeutics is more favorable than Ritter Pharmaceuticals.

Volatility and Risk

Odonate Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, suggesting that its stock price is 143% less volatile than the S&P 500.

Profitability

This table compares Odonate Therapeutics and Ritter Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Odonate Therapeutics beats Ritter Pharmaceuticals on 7 of the 9 factors compared between the two stocks.